Abstract
The article deals with the results of researches on the effect of the combination of ACE inhibitor (lisinopril) and calcium antagonist (amlodipine) when used in patients with high or very high cardiovascular risk. There is also considered the possibility of combined antihypertensive therapy with lisinopril/ amlodipine in combination with lipid-lowering therapy with rosuvastatin in patients with high and very high cardiovascular risk associated with metabolic syndrome and/or type 2 diabetes. Administration of the combination therapy significantly reduces blood pressure to the target level of 140/90 mmHg and reduces the SCORE scale ten-year risk of fatal cardiovascular disease in people with high and very high cardiovascular risk.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
